Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anixa BiosciencesSTU:CY71 +0.56%36 Market Cap is €91.42 Mil as of Jul. 14, 2026. GuruFocus rates STU:CY71 with a GF Score™ of 36/100. The stock has 3 warning signs investors should review. Among 1,423 Biotechnology companies, Anixa Biosciences ranks worse than 51.86% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Anixa Biosciences's share price for the quarter that ended in Apr. 2026 was €2.51. Anixa Biosciences's Shares Outstanding (EOP) for the quarter that ended in Apr. 2026 was 33.92 Mil. Therefore, Anixa Biosciences's market cap for the quarter that ended in Apr. 2026 was €85.15 Mil.
Anixa Biosciences's quarterly market cap
declined
from Oct. 2025 (€114.89 Mil) to Jan. 2026 (€85.00 Mil) but then
increased
from Jan. 2026 (€85.00 Mil) to Apr. 2026 (€85.15 Mil).
Anixa Biosciences's annual market cap
increased
from Oct. 2023 (€90.94 Mil) to Oct. 2024 (€101.74 Mil) and
increased
from Oct. 2024 (€101.74 Mil) to Oct. 2025 (€114.89 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Anixa Biosciences's Enterprise Value for Today is €78.47 Mil.
Anixa Biosciences (STU:CY71) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Anixa Biosciences Market Cap Related Terms
Anixa Biosciences Market Cap Historical Data
* Premium members only.
The historical data trend for Anixa Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:CY71 vs BMEA, PMN, ATRA: Market Cap Comparison
For the Biotechnology subindustry, Anixa Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anixa Biosciences Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Anixa Biosciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Anixa Biosciences's Market Cap for the fiscal year that ended in Oct. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anixa Biosciences (STU:CY71) has a Market Cap of €91.42 Mil as of Jul. 14, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Anixa Biosciences and its competitors. According to the industry distribution chart, Anixa Biosciences ranks #738 out of 1423 companies in the Biotechnology industry, placing it in the top 51.9%.
Is Anixa Biosciences' Market Cap too high?
Anixa Biosciences' current Market Cap is €91.42 Mil. Based on the distribution chart, Anixa Biosciences ranks #738 out of 1423 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Anixa Biosciences has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' Market Cap compare to BMEA and PMN?
According to the Biotechnology industry distribution chart, Anixa Biosciences ranks #738 out of 1423 companies for Market Cap. This places Anixa Biosciences in the lower half of its industry. The industry median Market Cap is 115.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 115.88, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Anixa Biosciences and its competitors. For the Biotechnology industry, the median Market Cap is 115.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anixa Biosciences's current Market Cap is €91.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (STU:CY71) has a current Market Cap of €91.42 Mil. The current Market Cap is €91.42 Mil. Anixa Biosciences' overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Anixa Biosciences (STU:CY71), the current Market Cap is €91.42 Mil as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
36GF Score
Get the complete analysis for STU:CY71
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CY71 has been successfully added to your 
